ライフサイエンスコーパス: epirubicin

1 rone, and the anthracyclines doxorubicin and epirubicin.

2 nge in HR or CO, compared to doxorubicin and epirubicin.

3 in the resistant counterparts in response to epirubicin.

4 tumors correlate with patients' response to epirubicin.

5 from patients who had complete responses to epirubicin.

6 breast cancer cells to paclitaxel but not to epirubicin.

7 to cisplatin, carboplatin, temozolomide, and epirubicin.

8 lls are highly resistant to mitoxantrone and epirubicin.

9 used such as daunorubicin, doxorubicin, and epirubicin.

10 ity in patients with breast cancer receiving epirubicin.

11 f the 1045 patients treated with accelerated epirubicin.

12 emical aptasensor for selective detection of epirubicin.

13 ctivation when compared with doxorubicin and epirubicin.

14 cycles of FEC (fluorouracil 500 mg/m(2) plus epirubicin 100 mg/m(2) plus cyclophosphamide 500 mg/m(2)

15 was VPA 140 mg/kg/d for 48 hours followed by epirubicin 100 mg/m2.

16 hose either FEC for eight cycles (n=1265) or epirubicin (100 mg/m(2) at 3-weekly intervals) for four

17 three cycles of fluorouracil (500 mg/m(2)), epirubicin (100 mg/m(2)), and cyclophosphamide (500 mg/m

18 treatment was 3 cycles of FEC (fluorouracil, epirubicin [100 mg/m(2) per dose], and cyclophosphamide)

19 receive three cycles of preoperative CT with epirubicin 120 mg/m(2) and ifosfamide 9 g/m(2) and granu

20 mly assigned to three preoperative cycles of epirubicin 120 mg/m(2) plus ifosfamide 9 g/m(2), and 160

21 t bypasses the low-yielding semisynthesis of epirubicin (4'-epidoxorubicin) and 4'-epidaunorubicin, i

22 s follows: ifosfamide 54 g/m(2) (both arms), epirubicin 450 mg/m(2), etoposide 1,350 mg/m(2) (six-dru

23 modified-dose EOC plus panitumumab (mEOC+P; epirubicin 50 mg/m(2) and oxaliplatin 100 mg/m(2) on day

24 up to eight 21-day cycles of open-label EOC (epirubicin 50 mg/m(2) and oxaliplatin 130 mg/m(2) on day

25 e 15 mg/kg intravenously on day 1) plus ECX (epirubicin 50 mg/m(2) intravenously on day 1, cisplatin

26 in combination with open-label chemotherapy (epirubicin 50 mg/m(2) intravenously; cisplatin 60 mg/m(2

27 The recommended dose for EOC + P is epirubicin 50 mg/m(2), oxaliplatin 100 mg/m(2), capecita

28 dose de-escalation was made to EOC + P DL-1 (epirubicin 50 mg/m(2), oxaliplatin130 mg/m(2), capecitab

29 nd three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area)

30 d capecitabine (ECX; four 3-weekly cycles of epirubicin [50 mg/m(2)] and cisplatin [60 mg/m(2)] intra

31 on to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3

32 treatment received fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2)

33 in 75 mg/m2 and paclitaxel 200 mg/m2) or EC (epirubicin 75 mg/m2 and cyclophosphamide 600 mg/m2) admi

34 were randomly assigned to receive either EP (epirubicin 75 mg/m2 and paclitaxel 200 mg/m2) or EC (epi

35 concomitant with four cycles of neoadjuvant epirubicin (75 mg/m(2)) plus docetaxel (75 mg/m(2)) and

36 es 1-4) and FEC (fluorouracil [500 mg/m(2)], epirubicin [75 mg/m(2)], and cyclophosphamide [500 mg/m(

37 mg/m(2) followed in both arms by four times epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2)

38 ree cycles of FEC (fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), and cyclophosphamide 600 mg/m(2))

39 /m(2)) every 3 weeks (DC) or three cycles of epirubicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2

40 eceive 3 cycles of fluorouracil (500 mg/m2), epirubicin (90 mg/m2), and cyclophosphamide (500 mg/m2),

41 The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy

42 The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial ex

43 ates were 72.7% (95% CI, 68.0% to 77.3%) for epirubicin alone and 79.5% (95% CI, 75.2% to 83.8%) for

44 n, and capecitabine chemotherapy: 50 mg/m(2) epirubicin and 60 mg/m(2) cisplatin on day 1 and 1250 mg

45 les of 90 mg/m(2) intravenously administered epirubicin and 600 mg/m(2) intravenously administered cy

46 CI 84.3-87.3) of patients receiving standard epirubicin and 87.1% (85.6-88.4) of those receiving acce

47 ates were 81.8% (95% CI, 77.7% to 85.9%) for epirubicin and 88.9% (95% CI, 85.5% to 92.2%) for epirub

48 Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior.

49 dvanced breast cancer, 3 months of high-dose epirubicin and cyclophosphamide (EC) administered every

50 axel with or without gemcitabine followed by epirubicin and cyclophosphamide achieved pCR compared wi

51 also the effect of sequencing the blocks of epirubicin and cyclophosphamide and paclitaxel (with or

52 gh addition of gemcitabine to paclitaxel and epirubicin and cyclophosphamide chemotherapy does not im

53 nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed b

54 59 (15%, 11-18) of 406 patients who received epirubicin and cyclophosphamide first (p=0.03).

55 he intention-to-treat population assigned to epirubicin and cyclophosphamide followed by docetaxel (E

56 thological complete response were 14.9% with epirubicin and cyclophosphamide followed by docetaxel an

57 phamide followed by docetaxel and 18.4% with epirubicin and cyclophosphamide followed by docetaxel pl

58 of 40 mm on palpation to receive neoadjuvant epirubicin and cyclophosphamide followed by docetaxel, w

59 hen epirubicin and cyclophosphamide; 208 had epirubicin and cyclophosphamide followed by paclitaxel a

60 ned via a central randomisation procedure to epirubicin and cyclophosphamide then paclitaxel (with or

61 0 (17%, 95% CI 14-21) of 404 patients in the epirubicin and cyclophosphamide then paclitaxel group ac

62 mly allocated 831 participants; 207 received epirubicin and cyclophosphamide then paclitaxel; 208 wer

63 f gemcitabine to accelerated paclitaxel with epirubicin and cyclophosphamide, and also the effect of

64 docetaxel, which was followed by 4 cycles of epirubicin and cyclophosphamide.

65 208 received paclitaxel and gemcitabine then epirubicin and cyclophosphamide.

66 aclitaxel (with or without gemcitabine) then epirubicin and cyclophosphamide.

67 n paclitaxel; 208 were given paclitaxel then epirubicin and cyclophosphamide; 208 had epirubicin and

68 ity when NR-160 was used in combination with epirubicin and daunorubicin.

69 ntegration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC.

70 n, DNA damage and apoptosis in comparison to epirubicin and doxorubicin.

71 d enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles.

72 null cells are hypersensitive to DNA damage, epirubicin and gamma-irradiation.

73 2) inhibition by equimolar concentrations of epirubicin and idarubicin was significantly less than th

74 t cancer cells in response to treatment with epirubicin and mitotic inhibitors.

75 reat analysis of standard versus accelerated epirubicin and per-protocol analysis of CMF versus capec

76 al and resistant colon cancer cell lines for epirubicin and to a lesser extent for SN-38 and mitoxant

77 P/ATR/CDK4/6 inhibitors, ionizing radiation, epirubicin, and camptothecin.

78 ollowed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to

79 ollowed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cyc

80 ne followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX).

81 bine and docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) or weekly paclita

82 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery.

83 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery.

84 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery.

85 ervals followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide at 3-week intervals.

86 bine into a regimen that contains docetaxel, epirubicin, and cyclophosphamide did not improve RFS sig

87 Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prolong RFS or

88 chemotherapy with 3 cycles of fluorouracil, epirubicin, and cyclophosphamide followed by 3 cycles of

89 tabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outco

90 xel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide or to the same chemothe

91 emotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival

92 of paclitaxel or six cycles of fluorouracil, epirubicin, and cyclophosphamide.

93 six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks.

94 ) of the 1070 patients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]

95 PURPOSE Cyclophosphamide, epirubicin, and fluorouracil (CEF) and doxorubicin and c

96 ollowed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients).

97 ollowed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747).

98 el followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other ha

99 Doxorubicin, daunorubicin, epirubicin, and idarubicin have been in clinical use for

100 apsulated drugs, which included doxorubicin, epirubicin, and vinorelbine.

101 he treatment of pediatric malignancies, with epirubicin-based regimens, or with high-dose anthracycli

102 in, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone).

103 associated with worse QOL than was standard epirubicin but only during treatment.

104 trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ ce

105 harmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patient

106 ntravenously on days 1-4]) or four cycles of epirubicin, cisplatin, and capecitabine (ECX; four 3-wee

107 e (rilotumumab group; n=304) or placebo plus epirubicin, cisplatin, and capecitabine (placebo group;

108 s were randomly assigned to rilotumumab plus epirubicin, cisplatin, and capecitabine (rilotumumab gro

109 igned patients 1:1 to receive peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or

110 operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50

111 harmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess p

112 mly assigned at a one-to-one-to-one ratio to epirubicin, cisplatin, and continuous-infusion fluoroura

113 rapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as

114 randomized to surgery alone or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in

115 whose tumor did not respond to preoperative epirubicin, cisplatin, and fluorouracil may be appropria

116 In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil,

117 A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) im

118 diotherapy (FU plus LV arm) or postoperative epirubicin, cisplatin, and infusional FU (ECF) before an

119 uracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplatin,and capecitabine) for AGC from the

120 vival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-ye

121 nthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, e

122 tamer conformation and formation of aptamer- epirubicin complex instead of aptamer on the modified el

123 pirubicin increased linearly with increasing epirubicin concentration, due to the switching in the ap

124 ydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin conjugate that induces immunogenic cell death

125 b-paclitaxel 125 mg/m(2) q1w, followed by 4x epirubicin + cyclophosphamide (90 mg + 600 mg) q2w; incl

126 tensified, dose-dense concomitant regimen of epirubicin + cyclophosphamide (historically called SIM)

127 TNBC patients, 23 received EC-D (4 cycles of epirubicin + cyclophosphamide followed by 4 cycles of do

128 n, followed by four cycles of doxorubicin or epirubicin + cyclophosphamide.

129 emcitabine (gemcitabine group; n=1576) or to epirubicin, cyclophosphamide, and paclitaxel (control gr

130 gned (1:1) to one of two treatment regimens: epirubicin, cyclophosphamide, and paclitaxel (four cycle

131 as a 3 h infusion on day 1 every 3 weeks) or epirubicin, cyclophosphamide, and paclitaxel plus gemcit

132 ients were enrolled and randomly assigned to epirubicin, cyclophosphamide, paclitaxel, and gemcitabin

133 emotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3

134 al phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered e

135 4 cycles (8 doses), followed by 4 cycles of epirubicin/cyclophosphamide, 90/600 mg/m2 (every 2 weeks

136 combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyc

137 e, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, or fluorouracil/doxorubicin

138 doses of VPA (days 1 through 3) followed by epirubicin (day 3) in 3-week cycles.

139 nthracyclines Doxorubicin, Daunorubicin, and Epirubicin decrease the transcription of nuclear factor

140 ancer (median age, 53 years) received a mean epirubicin dose of 304 mg/m(2), and 25 age/sex-matched c

141 treatment was stopped after reaching maximal epirubicin doses rather than progression in 13 (32%) of

142 al function (p=0.36), compared with standard epirubicin during treatment, but the effect did not pers

143 nts were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by

144 gned (1:1:1:1) to four cycles of 100 mg/m(2) epirubicin either every 3 weeks (standard epirubicin) or

145 signed to receive four cycles of 100 mg/m(2) epirubicin either every 3 weeks (standard epirubicin) or

146 how that two anthracyclines, doxorubicin and epirubicin, elicit distinct primary metabolic vulnerabil

147 at baseline, end of standard or accelerated epirubicin, end of CMF or capecitabine, and at 12 and 24

148 For example, 2nd generation HPMA copolymer-epirubicin (EPI) conjugates (2P-EPI) demonstrated comple

149 ydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (EPI) conjugates (ST-P-EPI); the latter is at

150 cessful design of polymer enhanced rituximab-epirubicin (EPI) conjugates targeted to non-Hodgkin lymp

151 ydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (EPI) conjugates.

152 Indocyanine green (ICG) and epirubicin (EPI) could co-self-assemble into small molec

153 Epirubicin (EPI) is less cardiotoxic compared with other

154 ons; four Anthracyclines: Doxorubicin (DOX), Epirubicin (EPI), Idarubicin (IDA) and Daunorubicin (DAU

155 e, methotrexate, and fluorouracil (CMF) with epirubicin followed by CMF (epi-CMF), were analyzed for

156 bicin and 88.9% (95% CI, 85.5% to 92.2%) for epirubicin followed by docetaxel.

157 alone and 79.5% (95% CI, 75.2% to 83.8%) for epirubicin followed by docetaxel; evidence of improvemen

158 the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cy

159 In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide,

160 lgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either cl

161 lgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either CM

162 Contemporary doses of epirubicin for breast cancer treatment result in a signi

163 ll trial, that substitution of docetaxel for epirubicin for the last three cycles of chemotherapy res

164 : doxorubicin, daunorubicin, idarubicin, and epirubicin for their ability to inhibit iPLA(2).

165 etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretamine, oxali platin, and

166 events between the accelerated and standard epirubicin groups (overall hazard ratio [HR] 0.94, 95% C

167 ested by applying them for the extraction of epirubicin hydrochloride (EPI) from plasma samples, foll

168 TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capec

169 as successfully assessed by determination of epirubicin in a human blood serum sample.

170 gylated liposomal-delivered doxorubicin, and epirubicin in HL-1 adult cardiomyocytes in culture as we

171 its expression level is low but inducible by epirubicin in MCF-7 cells.

172 inhibitor (HDACi), valproic acid (VPA), and epirubicin in solid tumor malignancies and to define the

173 hracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide

174 th this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts ca

175 er optimized conditions, the peak current of epirubicin increased linearly with increasing epirubicin

176 FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)ph

177 CF-7 and MCF-7Epi(R) cells more sensitive to epirubicin-induced cellular senescence.

178 FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance

179 FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance

180 e embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-ter

181 jugated with anthracycline anticancer agent, epirubicin, integrates the advantages of both chemosensi

182 Accelerated epirubicin led to worse physical function (p=0.0065), ro

183 ompatibility compared to free epirubicin and epirubicin-loaded nanoparticles.

184 ovel regimen IVE/MTX (ifosfamide, etoposide, epirubicin/methotrexate)-ASCT [corrected] was piloted fr

185 10% to 20% of patients include doxorubicin, epirubicin, mitomycin, cyclophosphamide, ifosfamide, cis

186 ly breast cancer compared with six cycles of epirubicin monotherapy.

187 of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin.

188 CF-1 mice (10/group) received doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg

189 h in PARG null-TS cells after treatment with epirubicin or sub-IC(50) doses of cisplatin and cyclopho

190 2) epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on

191 2) epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on

192 DNA cleavage was attenuated by doxorubicin, epirubicin, or mitoxantrone.

193 gate DSBs sustained by MCF-7 cells following epirubicin, owing to an enhancement in repair efficiency

194 Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n =

195 ion of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patie

196 Epirubicin, oxaliplatin, and capecitabine (EOC) is a sta

197 Epirubicin plus CMF is superior to CMF alone as adjuvant

198 0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone.

199 dverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not sign

200 ot significantly interact with the effect of epirubicin plus CMF.

201 4 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m(2)

202 ly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatmen

203 Patients were treated by sequential NAC (epirubicin plus cyclophosphamide followed by docetaxel w

204 s, followed by four cycles of doxorubicin or epirubicin plus cyclophosphamide Q2W or Q3W.

205 The NAC regimen consisted of 4 cycles of epirubicin plus cyclophosphamide, followed by 4 courses

206 cetaxel (100 mg/m(2) x four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m(2), respec

207 axel (75 mg/m(2)) and two cycles of adjuvant epirubicin plus docetaxel.

208 No exacerbation of epirubicin-related toxicities was observed.

209 OTUB1 can enhance the proliferative rate and epirubicin resistance through targeting FOXM1, as OTUB1

210 ion and de novo glutathione synthesis, while epirubicin-resistant cells display markedly increased bi

211 es with glutathione synthesis, compared with epirubicin-resistant counterparts that are more sensitiv

212 the protein and mRNA levels in MCF-7 and the epirubicin-resistant MCF-7 Epi(R) cells.

213 Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expressio

214 ind that FOXM1 expression is associated with epirubicin sensitivity and DSB repair.

215 agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated the expression of

216 sicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breas

217 tumors did not benefit from the addition of epirubicin to CMF.

218 nd toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane r

219 ote tumor retention of ND-complexes, prevent epirubicin toxicities and mediate regression of triple n

220 -naive patients with breast cancer receiving epirubicin versus sex- and age-matched healthy controls.

221 Epirubicin was associated with increased SBC risk (yes/n

222 Accelerated epirubicin was associated with worse QOL than was standa

223 % (85.6-88.4) of those receiving accelerated epirubicin were free from TTR events.

224 s absent in combinations of formaldehyde and epirubicin, which cannot form stable oxazolidines.

225 ) cells exposed to the chemotherapeutic drug epirubicin, which suggests a feed-forward loop to enrich

226 The interactions of epirubicin with aptamer on the AuNPs/Fe3O4@SiO2/DABCO/SP

227 t two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR)